IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 49,625 shares of the medical research company's stock after selling 19,201 shares during the quarter. Cresset Asset Management LLC's holdings in IQVIA were worth $9,752,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Tidal Investments LLC boosted its position in IQVIA by 9.3% during the third quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock worth $1,417,000 after acquiring an additional 509 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of IQVIA by 0.8% during the 3rd quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company's stock worth $49,532,000 after purchasing an additional 1,750 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. GAMMA Investing LLC grew its position in shares of IQVIA by 27.7% in the fourth quarter. GAMMA Investing LLC now owns 1,406 shares of the medical research company's stock valued at $276,000 after purchasing an additional 305 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its stake in IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Down 2.9 %

Shares of NYSE:IQV traded down $4.39 during trading on Friday, hitting $148.90. The company's stock had a trading volume of 1,677,229 shares, compared to its average volume of 1,469,448. The company has a market capitalization of $25.76 billion, a PE ratio of 19.85, a PEG ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock's 50-day moving average price is $163.91 and its two-hundred day moving average price is $188.25.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business's revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.54 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on IQV. Robert W. Baird lowered their price target on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a report on Wednesday. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $231.71.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.